The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus–Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial
Open accessAbstract
Background: Given the high mortality rate for patients with end-stage kidney disease receiving dialysis and the efficacy and safety of hepatitis C virus (HCV) treatments, discarded kidneys from HCV-infected donors may be a neglected public health resource. Objective: To determine the tolerability and feasibility of using direct-acting antivirals (DAAs) as prophylaxis before and after kidney transplantation from HCV-infected donors to non-HCV-infected recipients (that is, HCV D+/R- transplantation). Design: Open-label nonrandomized trial. (ClinicalTrials.gov: NCT02781649). Setting: Single center. Participants: 10 HCV D+/R- kidney transplant candidates older than 50 years with no available living donors. Intervention: Transplantation of kidneys from deceased donors aged 13 to 50 years with positive HCV RNA and HCV antibody test results. All recipients received a dose of grazoprevir (GZR), 100 mg, and elbasvir (EBR), 50 mg, immediately before transplantation. Recipients of kidneys from donors with genotype 1 infection continued receiving GZR-EBR for 12 weeks after transplantation; those receiving organs from donors with genotype 2 or 3 infection had sofosbuvir, 400 mg, added to GZR-EBR for 12 weeks of triple therapy. Measurements: The primary safety outcome was the incidence of adverse events related to GZR-EBR treatment. The primary efficacy outcome was the proportion of recipients with an HCV RNA level below the lower limit of quantification 12 weeks after prophylaxis. Results: Among 10 HCV D+/R- transplant recipients, no treatment-related adverse events occurred, and HCV RNA was not detected in any recipient 12 weeks after treatment. Limitation: Nonrandomized study design and a small number of patients. Conclusion: Pre- and posttransplantation HCV treatment was safe and prevented chronic HCV infection in HCV D+/R- kidney transplant recipients. If confirmed in larger studies, this strategy should markedly expand organ options and reduce mortality for kidney transplant candidates without HCV infection. Primary Funding Source: Merck Sharp & Dohme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Wolfe, R. A., Ashby, V. B., Milford, E. L., Ojo, A. O., Ettenger, R. E., Agodoa, L. Y. C., Held, P. J., & Port, F. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912023412303 · Cited by 5,371
Increases in drug and opioid-involved overdose deaths – United States, 2010-2015
Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm655051e1 · Cited by 2,194
US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Robinson, B., Abbott, K. C., Agodoa, L. Y. C., Albertus, P., Ayanian, J., Balkrishnan, R., Bragg-Gresham, J., Cao, J., Chen, J. L. T., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.004 · Cited by 2,191
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090
Self-citationDeceased-Donor Characteristics and the Survival Benefit of Kidney Transplantation
Merion, R. M. (2005) · JAMA · doi:10.1001/jama.294.21.2726 · Cited by 739
Roth, D., Nelson, D. R., Bruchfeld, A., Liapakis, A., Silva, M., Monsour, H., Martin, P., Pol, S., Londoño, M.-C., Hassanein, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00349-9 · Cited by 671
Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients
Goldberg, D. S., Abt, P. L., Blumberg, E. A., Van Deerlin, V. M., Levine, M., Reddy, K. R., Bloom, R. D., Nazarian, S. M., Sawinski, D., Porrett, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705221 · Cited by 364
Osburn, W. O., Fisher, B. E., Dowd, K. A., Urban, G., Liu, L., Ray, S. C., Thomas, D. L., & Cox, A. L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.017 · Cited by 360
Cited by
Ghany, M. G., Morgan, T. R., & Panel, A. H. C. G. (2020) · Hepatology · doi:10.1002/hep.31060 · Cited by 955
Long-Term Survival after Kidney Transplantation
Hariharan, S., Israni, A. K., & Danovitch, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2014530 · Cited by 664
Ultrasound‐Activated Sensitizers and Applications
Lin, X., Song, J., Chen, X., & Yang, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201906823 · Cited by 501
Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients
Woolley, A. E., Singh, S. K., Goldberg, H. J., Mallidi, H. R., Givertz, M. M., Mehra, M. R., Coppolino, A., Kusztos, A. E., Johnson, M. E., Chen, K., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812406 · Cited by 335
Improving the Supply and Quality of Deceased-Donor Organs for Transplantation
Tullius, S. G., & Rabb, H. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1507080 · Cited by 173
Metadata
- Authors
- Durand, C. M., Bowring, M. G., Brown, D. M., Chattergoon, M. A., Massaccesi, G., Bair, N., Wesson, R., Reyad, A., Naqvi, F. F., Ostrander, D., Sugarman, J., Segev, D. L., Sulkowski, M., & Desai, N. M.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2018-04-17
- Volume
- 168
- Issue
- 8
- Pages
- 533-540
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2789565767
- Cited by
- 302
- References
- 23
- FWCI
- 25.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus–Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. https://app.cochat.ai/papers/10.7326/m17-2871
- The paper
- Durand, C. M., Bowring, M. G., Brown, D. M., Chattergoon, M. A., Massaccesi, G., Bair, N., Wesson, R., Reyad, A., Naqvi, F. F., Ostrander, D., Sugarman, J., Segev, D. L., Sulkowski, M., & Desai, N. M. (2018). Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus–Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/m17-2871
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.